Meril Life Sciences has made a landmark advancement in India’s cardiovascular medical landscape with the launch of MyClip, the country’s first Transcatheter Edge-To-Edge Repair (TEER) system for mitral valve disease. Unveiled on June 14, 2025, during the Structural Heart Innovation event at the Meril Academy in Vapi, Gujarat, this device marks a major leap forward in treating severe Mitral Regurgitation (MR) for high-risk surgical patients.
Key highlights of the launch and its significance:
-
MyClip TEER System is a minimally invasive therapy that allows precise closure of the mitral valve flaps, reducing the backward flow of blood into the lungs. The procedure takes about an hour, and patients typically recover within 3–5 days.
-
The TEER system is targeted at patients with severe MR who are at high surgical risk, such as those with hypertension, diabetes, frailty, heart failure, or organ issues.
-
Meril is now a global frontrunner in transcatheter therapies, already leading with its Myval TAVI (Transcatheter Aortic Valve Implantation) system. With MyClip, Meril becomes the first Indian company to offer both valve replacement and repair platforms.
-
The COAPT study, cited at the event, showed TEER therapy reduces heart failure hospitalization rates and significantly lowers 2-year mortality when compared to standard medical therapy.
-
With currently only 150 TEER procedures annually in India and an estimated 1.5 million Indians suffering from severe MR, the market potential and medical need are both substantial—especially among younger patients (30–60 years old).
-
International pioneers like Prof. Ottavio Alfieri (widely considered the "Father of Mitral Valve Repair") and other global cardiology leaders participated in the event, endorsing India’s growing role in structural heart innovations.
-
Sanjeev Bhatt, Meril’s Senior VP for Corporate Strategy, emphasized early adoption and training initiatives, as well as public awareness campaigns such as #TreatmentZarooriHai featuring MS Dhoni to inform patients about the importance of timely MR treatment.
-
The event featured live case demos, interactive workshops, and clinical presentations, all centered on building a strong and scalable M-TEER ecosystem in India focused on accessibility, innovation, and excellence.
This milestone positions India not just as a consumer but as a contributor to global med-tech innovation, signaling a transformative era for minimally invasive heart valve therapies in the country.
